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ABSTRACT
Elastin like polypeptides (ELPs) are a class of naturally derived biomaterials that are nonimmunogenic, genetically encodable, and biocompatible making them ideal for a variety of
biomedical applications, ranging from drug delivery to tissue engineering. Also, ELPs undergo
temperature-mediated inverse phase transitioning, which allows them to be purified in a
relatively simple manner from bacterial expression hosts. Being able to genetically encode ELPs
allows for the incorporation of bioactive peptides and functionalization of ELPs. This work
utilizes ELPs for regenerative medicine and drug delivery.
The goal of the first study was to synthesize a biologically active epidermal growth
factor-ELP (EGF-ELP) fusion protein that could aid in the treatment of chronic wounds. EGF
plays a crucial role in wound healing by inducing epithelial cell proliferation and migration, and
fibroblast proliferation. The use of exogenous EGF has seen success in the treatment of acute
wounds, but has seen relatively minimal success in chronic wounds because the method of
delivery does not protect exogenous EGF from degradation, or prevent it from diffusing away
from the application site.
We created an EGF-ELP fusion protein to combat these issues. As demonstrated through
the proliferation of human skin fibroblasts in vitro, the EGF-ELP may be able to aid in the
treatment of chronic wounds. Furthermore, the ability of the EGF-ELP to self-assemble near
physiological temperatures could allow for the formation of drug depots at the wound site and
minimize diffusion, increasing the bioavailability of EGF and enhancing tissue regeneration.
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The objective of the second study was to create an injectable hydrogel platform that does
not require conjugation of functional moieties for crosslinking or biological activity. Hydrogels
are three-dimensional polymer networks that are able to absorb water and biological fluids
without dissolving. Their high water content gives them physical properties similar to soft
tissues, making them useful as scaffolds for cell migration and drug delivery vehicles. Injectable
hydrogels that crosslink in situ are particularly useful because they can form to the shape of the
defect, providing a near perfect fit. However, many hydrogel platforms cannot be crosslinked in
situ because cytotoxic crosslinking reagents are required. Additionally, hydrogels typically
require the chemical conjugation of crosslinking domains and bioactive peptides to the polymer
backbone, adding more steps and time required for hydrogel production.
We devised an injectable hydrogel platform that can be synthesized in a single step using
photoreactive ELPs as the polymer backbone. Leucine auxotrophic Eshcherichia coli expressed
ELPs containing photoleucine, a leucine analog and photoreactive diazirine crosslinker, which is
substituted for leucine periodically throughout the ELP sequence. Upon exposure to ultraviolet
radiation (~370 nm), photoleucine is able to form covalent crosslinks with amino acid side
chains, forming a polymer network for hydrogel formation. Additionally, recombinant growth
factors and morphogens can be encoded into the ELP sequence providing a simple method of
hydrogel functionalization for regenerative medicine applications.
The potential for this platform was demonstrated through in vivo crosslinking of
photoreactive ELPs in the expression hosts. Though the production of the photoreactive ELP was
not as forthright as originally assumed. The substitution of noncanonical amino acids typically
requires the auxotrophic expression hosts to be starved of the amino acid that they are
auxotrophic for. A noncanonical analog of said amino acid can then be supplemented into
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expression media, maximizing incorporation. In this investigation, it was found the addition of
photoleucine alone inhibited photoreactive ELP expression. ELP expression only occurred in the
presence of photoleucine if valine or leucine was also present in the media. Furthermore, valine
was found to aid the production of ELPs as much as leucine. It was postulated the bacterial
translational machinery might need to be altered for optimal ELP expression.
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CHAPTER 1: ELASTIN LIKE POLYPEPTIDES
Elastin is an extracellular matrix protein commonly found in the connective tissue of the
skin, ligaments, blood vessels, and lungs. Elastin provides these tissues with important physical
properties that allow them to function properly, primarily the ability to extend and elastic recoil
[1]. The precursor to the elastin polymer is tropoelastin, a monomer that contains hydrophobic
and hydrophilic domains which can be crosslinked via lysine residues. The crosslinked
tropoelastin monomers form insoluble elastin fibers [2].
Elastin like polypeptides (ELPs) are a class of recombinant proteins whose sequences are
derived from the hydrophobic domain of tropoelastin. A common sequence used in ELPs is
(VPGXG)n, where X is any guest residue other than proline (introduction of proline as the guest
residue prevents ELPs from inverse phase transitioning) [3] and n is the number of pentapeptide
repeats. This sequence is genetically encodable, allowing the guest residue and number of
pentapeptide repeats to be altered to give the ELP particular characteristics [2].
The (VPGXG)n sequence allows ELPs to undergo inverse phase transitioning, an
entropically driven phenomena that allows ELPs to solubilize in solution below their transition
temperature (Tt) and form insoluble aggregates above their Tt (Figure 1, next page) [2, 4]. The
formation of aggregates above the Tt is driven by the decreased organization of the solvent shell
above the Tt, shown in Figure 1 (next page). As a result of this change in entropy, the
hydrophobic portions of the ELPs collapse on one another, creating an ELP aggregate [4].
Additionally, the phase transition is reversible, allowing ELPs to transition between the two
phases depending on the temperature. The ability for ELPs to undergo reversible inverse phase
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transitioning can be exploited to purify the protein in a process known as inverse transition
cycling (ITC), a process where the protein is purified through a series of centrifugations below
and above the Tt [2].

T > Tt
= ELP
T < Tt
Aggregation

Solubilization

T > Tt
T < Tt

Figure 1 Inverse phase transition of ELPs. When below the transition temperature
(T<Tt) ELPs are soluble in solution. When the temperature is increased above the
transition temperature (T>Tt_) ELPs become insoluble and form aggregates.
While there are synthetic materials that also have the ability to undergo inverse phase
transitioning, ELPs do possess advantages over synthetic materials. The primary benefit is the
ability to genetically encode the ELP sequence, giving researchers complete control over the
chemical composition, and thus the physical characteristics of the ELP. For instance, by simply
changing the guest residue, ELP thermal characteristics can be modified [2]. It has been
demonstrated that when hydrophobic amino acids are substituted as the guest residue, the Tt is
depressed. Conversely, when charged or polar amino acids are substituted in the place of the
guest residue the Tt is elevated [5]. In addition to control over the thermal response of ELPs,
having the ability to manipulate the identity of the guest residue allows for incorporation of
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reactive amino acids or amino acid analogs which can be used for conjugation of biological
agents or crosslinking [2].
1.1 Recombinant DNA Techniques to Construct ELP Genes
As aforementioned, ELPs are a class of genetically encodable biopolymers containing a
repetitive sequence of the pentapeptide repeat (VPGXG)n. The production of ELPs, and other
protein-based polymers, requires the same five steps: (1) Construction of the plasmid to be used
for protein expression, (2) transformation of the constructed plasmid into cloning competent
cells, (3) verification that the plasmid has been transformed into cloning competent cells and that
no mutations have occurred within the plasmid, (4) transformation of the expression plasmid into
expression competent cells, and finally (5) protein expression and purification. The first step,
constructing the plasmid, can present problems for proteins that contain repetitive peptide
sequences, such as ELPs. The main issue is creating a gene for a large protein sequence from a
small gene fragment [6].
For instance, the gene for the ELP V50 contains a nucleotide sequence that encodes for 50
repeats of the pentapeptide VPGVG. Typically, the V50 gene would be constructed from a
smaller gene fragment, possibly a gene encoding five pentapeptide repeats of VPGVG (V5).
There are a multitude of methods used to synthesize large gene fragments from smaller gene
fragments; however, two of the more common techniques used for ELP gene construction are
concatemerization and recursive directional ligation.
1.1.1 Concatemerization
Concatemerization entails the ligation of a random number of identical monomeric gene
fragments to one another, though the number of monomers ligated can be highly influenced by
reaction conditions. This method is able to generate a collection of oligomeric genes composed
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of identical monomers during a single ligation. For concatemerization to be implemented, the
monomeric gene fragment to be self-ligated must contain single stranded overhang sequences at
the monomer’s head and tail that are the same length and complementary, but not identical.
Essentially, the overhang sequences must be cohesive, but nonpalindromic. This ensures the
monomers are ligated in a head-to-tail fashion, as opposed to a head-to-head or tail-to-tail
manner, which could alter the encoded amino acid sequence [6]. Concatemerization has been
widely used to construct plasmids for repetitive amino acid sequences. For instance,
concatemerization was used by Cappello et al when constructing a gene for a silk-like protein
that contained 160 repeats of the hexapeptide sequence GAGAGS [7].
To create the cohesive nonpalindromic overhangs, endonucleuase digestion via restriction
enzymes can be used. For instance, one of the more widely used restriction enzymes, Ban I,
recognizes the six base-pair sequence 5’-G/GTGCC (Ban I cleaves the sequence at the /). To
ensure head-to-tail ligation occurs, the monomer sequence that is to be oligomerized can be
flanked by the Ban I restriction site. The 5’ head and 5’ tail produced upon cleavage with Ban I
will contain cohesive nonpalindromic sequences, which will result in head-to-tail ligation [8]. In
addition, it has been demonstrated by McPherson et al that using restriction enzymes with the
ability to recognize interrupted palindromes can be used to make certain that head-to-tail
ligations takes place [9]. Figure 2 (next page) illustrates the construction of a gene library using
concatemerization.
As aforementioned, concatemerization has proven to be a valuable technique for
generating different sized polypeptides that contain repeats of identical monomeric sequences
during a single ligation; however, there are major limitations when using this technique. One
major shortcoming is the lack of precise control over the number of monomers that ligate;
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though, this is only an issue when there is a need for precise control over the number of
monomeric repeats present in the new gene. Another drawback is there is no control over the
sequence generated by ligation of the monomers, which is why concatemerization can only be
conducted using identical monomers [6]. However, there are other recombinant DNA techniques
that are able to overcome these drawbacks, such as recursive directional ligation.
Restriction
Sites
Restriction Enzyme
Digestion

Monomeric Gene
Fragment

Concatemerization

Ligation

Gene Library Consisting of Various
Amounts of Monomeric Gene Inserts

Figure 2 Creating gene libraries via concatemerization. Following restriction enzyme
digestion, the monomeric gene fragment undergoes concatemerization to produce a
library of genes containing various numbers of monomeric gene fragments.
1.1.2 Recursive Directional Ligation
Similar to concatemerization, recursive directional ligation (RDL) is a recombinant DNA
technique used to construct genes for peptides containing repetitive amino acid sequences. Both
methods utilize head-to-tail ligation to produce genes and make use of restriction enzymes that
cleave interrupted palindrome sequences. However, there are several differences between the
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two techniques. Unlike concatemerization, RDL allows for precise control over the number of
monomeric repeats inserted into the gene and the sequence in which monomers are inserted into
the gene. Hence, RDL is used to construct genes encoding repetitive polypeptides that must be a
specified size and sequence [6].
Typically, the same procedure is followed when using RDL, regardless of the number of
peptide repeats or the sequence. To start, the monomer gene encoding the peptide sequence to be
oligomerized is ligated into a cloning vector in such a way that the monomer gene is flanked by
two different restriction enzyme recognition sites (RE1 and RE2). To begin oligomerization, the
monomer gene is removed from the cloning vector using RE1 and RE2. Additionally, a separate
aliquot of the cloning vector containing the monomer gene is cut using either RE1 or RE2,
producing a linearized vector. The monomer insert can then be ligated in a head-to-tail fashion
into the linearized vector. This procedure can be repeated until the desired number of peptide
repeats has been inserted [10]. Figure 3 (next page) demonstrates the general procedure used for
RDL.
Additionally, a gene containing a different peptide sequence can be ligated into the
linearized vector as long as the overhang sequences are cohesive and nonpalindromic in relation
to the linearized vector [6]. While RDL can be tedious when creating genes containing large
numbers of monomeric gene fragment repeats, the ability to control the number of monomeric
gene fragments ligated into the vector and insert gene fragments encoding different peptide
sequences makes RDL particularly useful for the construction of ELP genes, as demonstrated by
Meyer and Chilkoti [10]. Furthermore, a combination of concatemerization and RDL can be used
to synthesize genes containing multiple repeats of monomeric gene fragments.
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RE
1

RE
2

Plasmid
1

RE1

RE1

RE2

RE2
Plasmid
2

Plasmid 1:
RE1 & RE2
Plasmid 2:
RE1 Only

RE1
= Gene
1

RE2
RE1

RE2

+

Plasmid
2

Ligation

Plasmid
2

= Gene
2

Figure 3 Plasmid construction using recursive directional ligation (RDL). A gene
composed of Gene 1 and Gene 2 can be designed using RDL. Restriction sites are
conserved while no additional restriction sites are formed.
1.2 Recombinant Protein Purification
1.2.1 Affinity Chromatography
One of the most common processes used to purify recombinant proteins is affinity
chromatography [10]. Affinity chromatography is a liquid chromatographic technique that
utilizes nonbiologcal or biological interactions to isolate specific compounds from complex
solutions [11]. The reactions are highly specific and are normally reversible, similar to an
antibody-antigen interaction [12].
In affinity chromatography, an affinity ligand specific for the target compound is
immobilized on a solid phase, and the liquid solution containing the desired compound is passed
over or through the immobilized phase. As the solution passes through the immobilized phase,
the binding agent will bind the desired product and isolate it from the solution. The target
compound is then eluted from the ligand and immobilized phase using one of two methods.
Specific elution is a method that weakens the target-ligand interaction by competing for the
7

ligand or target compound, eventually leading to the target compound being released from the
ligand. Nonspecific elution aims to decrease the association constant between the target
compound and ligand by altering the environmental conditions surrounding the complex. This
can be done by manipulating the salt concentration or pH to reduce hydrogen bonding,
hydrophobic interactions, and electrostatic interactions [12].
Affinity chromatography has been used to purify ELPs that do not retain the inverse
transition property. For example, ELPs can be labeled with a His-tag, which can be used to
purify the protein via metal-ion affinity chromatography [13]. While affinity chromatography
can be used for laboratory-scale protein purification, there are economical and technical
limitations the make it difficult to scale-up to high capacity applications [10].
1.2.2 Inverse Transition Cycling
Inverse transition cycling (ITC) is a protein purification method that utilizes the inverse
phase transitioning property of ELPs. ITC provides many economic and technical benefits over
other protein purification methods, such as affinity chromatography [10]. During ITC, ELPs are
isolated from the bacterial cell lysate in a series of hot centrifugations (above the Tt) and cold
centrifugations (below the Tt). When a cold centrifugation is conducted, the ELP is solubilized
and insoluble impurities can be removed [2]. Reducing agents (such as DTT) can be added prior
to the cold centrifugation if the ELP contains cysteines that are able to form disulfide bonds. The
formation of disulfide bonds may reduce the solubility of ELP in solution, thus the reduction of
disulfide bridges is crucial for purifying cysteine-containing ELPs [14].

The supernatant

containing the ELP is then heated above the Tt and undergoes a hot centrifugation. During the
hot centrifugation the ELP transitions to form an insoluble aggregate, which forms a pellet,
isolating the ELP from soluble impurities that are present in the solution. Additionally, salt can
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be added to the supernatant prior to the hot centrifugation to lower the Tt, thus aiding in the
formation of the insoluble ELP aggregate [2].
After the hot centrifugation, the ELP pellet can be resuspended in cold buffer if
additional ITC cycles need to be completed, or DI water if the ITC process is complete. It
typically takes multiple cycles of ITC to purify the ELP to sufficient levels [2]. After
resuspension in DI water, the ELP solution is dialyzed against DI water for 18-24 hours to
remove any salts or reducing agents that may be present. The ELP is then lyophilized so that it
can be stored at room temperature. The ITC process is described in Figure 4 (below).

Bacterial
Lysate
- Cold spin

Insoluble cellular
debris

Supernatant containing
ELP
- Add salt
- Hot Spin

Soluble
impurities

- Resuspend in PBS
- Add reducing agents, if necessary
- Repeat 2-3 times

Pellet containing
ELP
- Resuspend in DI H2O
- Dialyze against DI H2O
- Lyophilization

Purified
ELP

Figure 4 Inverse transition cycling (ITC). ELPs are purified through series of cold and
hot centrifugations. Salts can be added to aid ELP precipitation while reducing agents
can increase ELP solubility.
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1.3 Elastin Like Polypeptides in Biomedical Applications
Due to their high level of tunability and biocompatibility, ELPs are beginning to show
great value in variety of biomedical applications, such as drug delivery and tissue engineering
applications [15-17]. For instance, bioactive peptides, such as growth factors, have been fused to
ELPs and have been shown to retain the biological activity of the growth factor. These growth
factor-ELP (GF-ELP) fusion proteins have been also been shown to possess the inverse phase
transition property of ELPs. This provides a simple method for the production and purification of
growth factors, and can also aid in growth factor delivery as the self-aggregation of GF-ELPs can
increase the bioavailability of GFs [18].
As aforementioned, ELPs can also be functionalized by substituting reactive amino acids
in the ELP sequence at the guest residue position. For example, cysteine and lysine have been
substituted to enable crosslinking and drug conjugation to ELPs [14, 19]. Though, this is not
limited to canonical amino acids. Reactive noncanonical amino acid analogs can also be
incorporated in the ELP sequence using auxotrophic expression hosts and expression media
supplemented with the noncanonical analog. For example, incorporation of photoreactive
noncanonical amino acid analogs can enable crosslinking of ELPs upon exposure to ultraviolet
radiation [20]. In this thesis, we aimed to exploit the fact ELPs can be functionalized by simply
altering the ELP sequence to create innovative drug delivery platforms.
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CHAPTER 2: DEVELOPMENT OF EPIDERMAL GROWTH FACTOR-ELASTIN LIKE
POLYPEPTIDE FUSION PROTEIN
2.1 Introduction
2.1.1 Epidermal Growth Factor and the Epidermal Growth Factor Receptor
Epidermal growth factor (EGF) is a 53 amino acid single-chain polypeptide discovered
by Dr. Stanley Cohen in 1962 while studying the effects of mice submaxillary gland extract on
newborn mice [21, 22]. EGF is a member of a family of growth factors, the EGF family, that are
able to bind to the epidermal growth factor receptor (EGFR), a tyrosine kinase transmembrane
protein found throughout the epidermis, especially in the basal layer. Upon binding EGF, the
EGFR undergoes dimerization and autophosphorylation, activating the mitogen-activated protein
kinase pathway (MAPK). Ultimately, activation of the MAPK pathway influences the
phosphorylation of various transcription factors and calcium release of protein kinase C [23].
Also, activation and dimerization of the EGFR due to EGF binding has been shown to
play a crucial role in epidermal regeneration and corneal epithelial regeneration through
enhancing epithelial cell proliferation and migration, stimulating the production of extracellular
matrix proteins, and increasing fibroblasts proliferation [23].
2.1.2 Epidermal Growth Factor and Regenerative Medicine
The use of exogenous EGF in acute wound healing was originally examined in 1973 by
Savage and Cohen, when they demonstrated corneal epithelial hyperplasia can be induced using
EGF [24]. Since then, the use of exogenous EGF has shown promise in the treatment of acute
surgical wounds in rabbits [25], corneal epithelial wounds [26-28], and partial thickness burn
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wounds [29]. However, the use of exogenous EGF to aid in the treatment in chronic wounds,
such as diabetic ulcers or venous ulcers, has not been as successful.
Exudative fluid withdrawn from chronic wounds has shown, compared to acute wounds,
an increased level in protease activity and diminished EGF activity [30, 31]. This hints at the
possibility that EGF is degraded by excessive protease activity within the microenvironment of
chronic wounds. As demonstrated by Falenga et al., the topical administration of aqueous EGF
solutions to venous ulcers can increase the rate of re-epithelialization and decrease wound size
when compared to control groups. However, the results were not statistically significant, and
were not nearly as prominent as results seen in acute wounds [32]. Due to this, alternative
delivery systems have been investigated.
As aforementioned, the microenvironment in chronic wounds leads to the excessive
degradation of growth factors that enter the wound. The high rate of degradation means there is
not a high enough concentration of EGF present at the wound site to make a significant
difference in healing, and the growth factor is not present in the wound long enough for its
presence to be detected [33]. Additionally, when EGF is administered using simple bolus
delivery methods, such as topical application [32] or intralesional injections [34], it is able to
easily diffuse away from the wound decreasing the local concentration of EGF, thus minimizing
its impact on wound healing. This can lead to using large quantities of EGF and having to
reapply the treatment continuously, potentially leading to tumor development and making the
therapy expensive [33].
To combat these issues, delivery systems utilizing hydrogels with EGF encapsulated
within the polymer network have been investigated. While there has been moderate success
using this method, there is little control over the release of EGF from the polymer network,
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resulting in a burst release profile of EGF [35]. While there may be some instances where a burst
release profile is preferred, most applications require the ability to control the release of EGF to
ensure the growth factor is present throughout the healing process [26]. To achieve this, growth
factor delivery vehicles that will allow for the covalent binding, or at least physical interactions,
between growth factors and a scaffold will need to be developed.
2.1.3 Utilization of ELP Fusion Proteins for Drug Delivery
The biocompatibility and ability to self-assemble associated with ELPs makes them ideal
for in vivo applications. Additionally, since ELPs are genetically encodable, it is relatively
simple to fuse other biologically significant peptides to ELPs creating ELP fusion proteins, as
illustrated in Figure 5 (below). These ELP fusion proteins have been shown to retain not only the
inverse phase transition property of traditional ELPs, but also the biological activity of the fused
peptide [18]. Hence, ELP fusion proteins have the potential to serve as all-in-one drug delivery
systems, containing the drug and delivery vehicle without the need for chemical conjugation.
Prokaryotic
promoter

Growth Factor
(GF)

Elastin Like Peptide
(ELP)

= GF peptide
=
ELP

T > Tt

Figure 5 GF-ELP gene design and aggregation. The top of figure shows the
sequence the genes are in when inserted into the expression vector. At the bottom,
the aggregation of GF-ELP fusion proteins above their Tt is illustrated.
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The ability to create ELP fusion proteins that retain the biological activity of peptides and
the inverse phase transition property of ELPs makes them ideal candidates for localized drug
delivery. There are a number of ways ELP fusion proteins can be utilized for local drug delivery.
One method has seen the creation of coacervate drug depots via aggregation of ELP fusion
proteins for treatment of osteoarthritis [36] and neuroinflammation [37]. Furthermore,
keratinocyte growth factor-ELP fusion protein coacervates have been used in conjunction with
fibrin hydrogels for delivery of keratinocyte growth factor-ELP fusions to wounds in animal
models [18]. Another method utilized for the local delivery of ELP fusion proteins is chemically
crosslinking ELP domains to create a three-dimensional scaffold [38].
2.2 Project Objective
The aim of this project was to create a biologically active EGF-ELP fusion protein that
could address the issues connected with the use of exogenous EGF in regenerative medicine.
Currently, the administration of exogenous EGF is carried out by either a simple injection or
topical application. Unfortunately with these techniques, EGF can be rapidly degraded and can
diffuse away from the application site with relative ease, leading to a decreased local
concentration of EGF and minimal improvements as far as tissue regeneration is concerned.
The EGF-ELP fusion protein produced was meant to address these complications. By
creating an EGF-ELP fusion protein, the biological activity of EGF should be kept intact while
the characteristics of ELPs are also maintained, meaning the EGF-ELP fusion protein will be
able to self-assemble near physiological temperatures making it an ideal vehicle for the local
delivery of EGF to wounds. To investigate the potential use for the EGF-ELP in regenerative
medicine, the fusion protein was purified, and its thermal and biological properties were
analyzed.
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2.3 Materials and Methods
2.3.1 Materials
EGF and V40C2 (ELP) genes were purchased from GenScript. Restriction enzymes and
other enzymes used for cloning were purchased from New England Biolabs. For purification of
DNA after gel electrophoresis, a gel extraction kit produced by Qiagen was used. For cell culture
purposes, fetal bovine serum (FBS) and Dulbecco’s Modified Eagle’s Medium (DMEM) were
purchased from Life Technologies, and antibiotic-antimycotic (AA) solution was purchased from
Corning CellGro. Dr. Eric Haura from Moffitt Cancer Center generously donated A549
adenocarcinomic alveolar basal epithelial cells and A431 epidermoid carcinoma cells. Human
skin fibroblast were purchased from ATCC. Ethidium homodimer was purchased from Life
Tehnologies. Fluorescent photographs for migration and cell counting experiments were taken
using an EVOS® FL Digital Inverted Microscope. An Eon ™ High Performance Microplate
Spectrophotometer (Biotek) was used for optical density readings at 350 nm (OD350), while a
Synergy Multi-Mode Reader (Biotek) was used for fluorescence readings during A549 and
fibroblasts proliferation studies. Dynamic light scattering was conducted using a Zetasizer Nano
S (Malvern, UK).
2.3.2 EGF-ELP Gene Construction
The EGF gene (amino acid sequence in Appendix A) was sent in a pUC57 plasmid with
PflMI and BglI restriction enzyme sites flanking the gene. PflMI and BglI were used to remove
the EGF gene from the pUC57 plasmid, and BglI was used to linearize the ELP pUC19 plasmid.
After digesting the plasmids with the required restriction enzymes, gel electrophoresis was used
to separate DNA fragments. The EGF gene and linearized ELP gene were purified using a gel
extraction kit. Once both genes were purified from the gel, the EGF gene was ligated into the
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linearized ELP pUC19 plasmid and transformed into Top10f competent cells (Invitrogen). The
ligation was carried out so that EGF was at the N-terminus of the fusion protein. Polymerase
chain reaction (PCR) was used to ensure the EGF gene was successfully ligated into the
linearized ELP pUC19 plasmid. Figure 6 (below) illustrates the process of creating the EGF-ELP
pUC19 vector.
EL
P

F
EG

pUC57

pUC19

EGF gene was
excised from pUC57
using BglI and PflMI

ELP-pUC19 was
linearized using BglI
EGF insert was ligated into
linearized V40C2-pUC19
plasmid

F
EG

ELP

pUC19

EGF-V40C2 sequence was excised
from pUC19 and ligated into
linear pET25b(+) vector for
fusion protein expression

Figure 6 Producing the EGF-ELP fusion protein gene. The EGF gene was excised and
inserted into a linearized ELP-pUC19 cloning vector. Once the EGF-ELP pUC19
vector was created, the EGF-ELP gene fragment was excised and ligated into a
linearized expression vector for ELP expression.
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The EGF-ELP pUC19 plasmid was then cut using the restriction enzymes PflMI and BglI
to excise the EGF-ELP gene. The EGF-ELP gene was purified using the same gel extraction
method described previously. The isolated EGF-ELP gene was then ligated into a linearized
pET25b(+) expression vector and transformed into Top10f competent cells. PCR was again used
to ensure the EGF-ELP gene was successfully ligated into the pET25b(+) expression vector. The
EGF-ELP pET25b(+) vector was sent for sequencing to confirm the EGF-ELP gene was
successfully ligated and no mutations were present. The EGF-ELP pET25b(+) vector was then
transformed into BLR(DE3) competent cells (Invitrogen) for expression.
2.3.3 EGF-ELP Expression and Purification
Escherichia coli BLR(DE3) competent cells containing the EGF-ELP pET25(b+)
plasmid were cultured in 50 mL of TB media (yeast extract: 24 g/L, tryptone: 12 g/L, potassium
phosphate monobasic: 2.31 g/L, potassium phosphate monobasic: 12.54 g/L, proline: 11.5 g/L,
glycerol: 4 ml/L, and carbenicillin: 100 µg/ml) overnight. The next day, the starter culture was
added to 1 L of fresh TB media and cultured for 18 hours at 37°C and 180 RPM. E. coli was
collected by centrifugation (3,000 G’s, 4°, 20 minutes) and resuspended in 160 mL of 4°C
phosphate buffered saline (PBS). Bacteria was then lysed using a Model 505 Sonic
Dismembrator (Fisher Scientific) set to run at 50% amplitude for 12 minute cycles (3 cycles
total, pulse on 59 seconds, pulse off 59 seconds). After each cycle, the bacterial lysate was
cooled at 4°C for 40 minutes. To remove cellular debris, the bacterial lysate was centrifuged
(20,000 G’s, 4°C, 20 minutes) and the supernatant containing EGF-ELP was collected.
After collecting the supernatant, EGF-ELP was purified using inverse temperature
cycling (ITC). The supernatant was supplemented with 1 M NaCl and placed in a water bath at
45°C for 40 minutes. The EGF-ELP solution underwent a hot spin (20,000 G’s, 40°C, 10
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minutes), after which the supernatant was discarded and the pellet was resuspended in 100 mL
PBS containing 10 mM dithiothreitol (DTT) at 4°C. DTT served as a reducing agent to prevent
the formation of disulfide bonds, which would decrease the solubility of the EGF-ELP. Prior to
cold spins (20,000 G’s, 4°C, 20 minutes), the EGF-ELP solution was cooled at 4°C for 1 hour.
The cycle of hot and cold spins was conducted 3 times, or until cellular debris was no longer
visible after centrifugation. After the last hot spin, the EGF-ELP pellet was resuspended in 50
mL deionized (DI) H2O at 4°C. The EGF-ELP solution was then dialyzed against DI H2O for 18
hours at 4°C to remove any salts or DTT that may be present. After dialysis, the EGF-ELP was
lyophilized.
2.3.4 Total Protein Stain and Western Blot Analysis
Total protein stains and western blot analysis were conducted using sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Samples were taken from various
stages of ITC and were analyzed by SDS-PAGE (12% acrylamide gels). For western blots, antiEGF antibody (Cell Signal) was used to label EGF-ELP. Horseradish peroxidase linked (HRP)
anti-rabbit antibody (Cell Signal) was used to label anti-EGF antibody, and a chemiluminescent
signal was produced using LumiGLO ® Reagent and peroxide (Cell Signaling Technologies).
2.3.5 EGF-ELP Transition Temperature
EGF-ELP was dissolved in cold PBS (~4°C) to create a 5 µM solution and was then
filtered using a 0.45 µm filter. Dynamic light scattering (DLS) was used to analyze the sample as
the temperature was increased from 10°C to 40°C in 5°C increments. The sample was allowed to
equilibrate for 15 minutes once the DLS apparatus reached the desired temperature. Once the
sample had equilibrated, the DLS apparatus analyzed the EGF-ELP sample and recorded the
derived count rate (kcps) twice at each temperature.
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2.3.6 Elastic Behavior of EGF-ELP
EGF-ELP was diluted in cold PBS (~4°C) to a concentration of 15 µM. 100 µl was then
loaded in a round bottom 96 well plate, which was then placed in the spectrophotometer. The
optical density at 350 nm (OD 350) was measured as the EGF-ELP solution was heated from
26°C to 42°C in increments of 2°C. The OD 350 was also measured as the solution was cooled
from 42°C to 26°C in increments of 2°C. The EGF-ELP solution was shaken for 30 seconds and
allowed to equilibrate for 10 minutes at each temperature before the OD 350 was measured.
2.3.7 EGF-ELP Size Characterization
A 5 µM EGF-ELP solution was prepared using cold PBS (~4°C) and filtered using a 0.45
µm filter. DLS was used to analyze the EGF-ELP solution at 15°C (below the Tt) and 37°C
(above the Tt). The EGF-ELP sample equilibrated at each temperature for 15 minutes prior to
being analyzed. After equilibration, the EGF-ELP solution was analyzed three times at each
temperature. The particle size distribution (mean intensity) and polydispersity index (PDI) were
calculated by the Zetasizer Nano S software.
2.3.8 A549 Proliferation and Migration
For the A549 proliferation study, A549 cells were seeded in a 48 well plate at 15,000
cells/well in DMEM + 10% FBS + 1% AA for 24 hours. Next, cells were washed with 1x PBS
and serum starved for 24 hours. Cells were then treated with serum free media, and various
amounts of ELP, EGF-ELP, and recombinant EGF (rEGF) for 48 hours. 24 hours into treatment,
bromodeoxyuridine (BrdU) was added to the wells. After 48 hours, a BrdU assay was conducted
to determine the amount of BrdU incorporated into newly synthesized DNA by measuring the
fluorescence at 450 nm.
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For the migration experiment, cells were prepared by seeding 10,000 cells/well in
DMEM + 10% FBS + 1% AA. After 24 hours cells were washed with 1x PBS and serum starved
for an additional 24 hours. Following serum starvation, cells were treated with EGF-ELP or ELP
(5 µM). After 48 hours of treatment, cells were treated with calcein and incubated at 37°C for 30
minutes. After incubation, photographs were taken at 10x and 20x.
2.3.9 Inhibition of A431 Proliferation

Figure 7 Picture locations in 48 well plate. After staining with NucBlue and ethidium
homodimer, and 30 minutes of incubation at 37°C pictures were taken at 10x at the
described locations in wells.
A431 epidermoid carcinoma cells were seeded in a 48 well plate at 10,000 cells/well in
DMEM + 10% FBS + 1% AA for 24 hours. Cells were then washed with 1x PBS and cultured in
2% FBS for 24 hours. After 24 hours, cells were treated with different concentrations of ELP and
EGF-ELP in 2% FBS for 48 hours. Cell nuclei were then stained with NucBlue (2 drops/ml
media) (Life Technologies) and dead cells were stained with ethidium homodimer (1:500
dilution). Cells were then incubated at 37°C for 30 minutes. 9 pictures/well were taken at 10x
magnification as shown in Figure 7 (above). Images were then analyzed using ImageJ software
and a macro created by Raul Iglesias.
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2.3.10 Human Skin Fibroblast Proliferation
Human skin fibroblast were seeded in a 48 well plate with 20,000 cells/well in DMEM +
10% FBS + 1% AA. After 24 hours, cells were serum starved in DMEM + 1% AA for 48 hours.
Following serum starvation, cells were treated with various amounts of EGF-ELP, ELP, and
recombinant EGF (rEGF), for 48 hours in serum-free culture. Following treatment, cell
proliferation was measured using a Hoescht assay. Fluorescence changes were recorded using an
excitation wavelength of 360 nm and an emission wavelength of 460 nm.
2.3.11 Statistical Analysis
Statistical significance for biological activity assays was determined using the p-value
calculated from ANOVA.
2.4 Results
2.4.1 EGF-ELP is Purified Using Inverse Transition Cycling
The total protein stain displayed in Figure 8 (next page) shows the total protein content
from multiple phases throughout the inverse transition cycling (ITC) purification process. Table
1 (next page) contains descriptions of the contents of each lane in Figure 8. The sample in Lane 1
was taken from the bacterial lysate and contains high protein content, as shown by the intense
signal and lack of distinct protein bands. The samples used in Lane 2 and Lane 3 were taken
during the later stages of ITC, with the sample in Lane 3 being taken after Lane 2. The protein
content in Lane 2 appears to be similar to the protein found in Lane 1, indicating high protein
content. In contrast, Lane 3 contains less protein than the bacterial lysate and Lane 2, and a
single band between 15 kDa and 35 kDa is apparent. This demonstrates that ITC does remove
impurities as the cycle progresses. Lane 4 contains the lyophilized EGF-ELP. The protein sample
at this stage has been through the entire ITC process, dialyzed for 18 hours, and lyophilized.
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Lane 4 contains a single band at approximately 30 kDa, demonstrating it is possible to
successfully remove impurities while purifying the EGF-ELP using ITC.
Table 1 Lane descriptions for Figure 8
Lane

Description

L

Biotin Ladder

1

Bacterial Lysate

2

Cold Supernatant

3

Hot Pellet

4

Lyophilized EGF-ELP

35 kDa

Purified
EGF-ELP

15 kDa

L

1

2

3

4

Figure 8 ITC is able to remove impurities from bacterial lysate. Samples from various
stages of ITC were separated via gel electrophoresis on a 12% SDS-PAGE gel.
To confirm EGF-ELP was the protein isolated during ITC, samples from several stages of
ITC were taken and underwent western blot analysis using anti-EGF. Figure 9 (next page)
provides information pertaining to the ability of the EGF-ELP to be purified efficiently via ITC,
and Table 2 (next page) provides information regarding the contents of each sample. The protein
bands near 30 kDa indicate the presence of EGF-ELP (MW=26.7 kDa). Figure 9 shows the EGFELP is present in the bacterial lysate after sonication. The western blot also shows the EGF-ELP
did not solubilize completely as it is present in the cold pellet (Lane 2) and cold supernatant
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(Lane 3) in roughly equal amounts after the first cold centrifugation. Additionally, the protein
bands present in the hot pellet (Lane 4) and hot supernatant (Lane 5) indicate the EGF-ELP is
present in both samples after the first hot centrifugation. However, the signal in the hot pellet is
more intense than the signal in the hot supernatant, indicating there is a larger quantity of the
EGF-ELP in the hot pellet. Finally, the band seen in the lyophilized product demonstrates the
final product contains the EGF-ELP (Lane 6), and the minimal background noise indicates there
are relatively few impurities present in the lyophilized EGF-ELP product.
Table 2 Lane descriptions for Figure 9
Lane

Description

L

Biotin Ladder

1

Bacterial Lysate

2

Cold Pellet

3

Cold Supernatant

4

Hot Pellet

5

Hot Supernatant

6

Lyophilized EGF-ELP

30 kDa
L
1
2
3
4
5
6
Figure 9 EGF-ELP can be purified via ITC. Samples form various stages of ITC were
collected and subjected to western blot analysis to detect the presence of EGF-ELP.
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2.4.2 EGF-ELP Transitions Below Physiological Temperature
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Figure 10 EGF-ELP transition temperature. Dynamic light scattering (DLS) was used to
measure the mean count rate at temperatures in intervals of 5°C between 5°C-40°C. A
25 µM sample of EGF-ELP was used.
The transition temperature of the EGF-ELP was determined using dynamic light
scattering (DLS). The mean count rate of a 25 µM sample was recorded over a temperature range
of 10°C-40°C in 5°C intervals, and plotted in Figure 10 (above). An increase in derived count
rate corresponds to the transition of EGF-ELP from monomers to aggregates. From 10°C-25°C,
the mean count rate stays fairly constant at approximately 200 kilocounts per second (kcps).
Once the temperature reached 30°C, the mean count rate increased from 200 kcps to 850 kcps,
indicating the aggregation of EGF-ELP’s. The transition temperature likely lies between 30°C35°C. As the temperature was increased further to 35°C and 40°C the mean count rate increased
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to 1250 kcps and 2600 kcps, respectively. The continued increase in mean count rate denotes a
further increase in EGF-ELP aggregate size.
2.4.3 EGF-ELP Retains Elasticity of ELPs

Figure 11 Thermoresponsive behavior of EGF-ELP. The OD 350 was measured while
increasing the temperature from 26°C-42°C and while decreasing the temperature from
42°C-26°C.
Figure 11 (above) shows the optical density at 350 nm (OD 350) for a 15 µM solution of
EGF-ELP. The OD 350 was measured as the EGF-ELP solution was heated from 26°C-42°C and
then cooled from 42°C-26°C in increments of 2°C. As the sample was heated from 26°C-42°C,
the OD350 value increased from 0.152 (+/- 0.006) to 1.322 (+/- 0.004), indicating the formation
of EGF-ELP aggregates. Though, the OD 350 value did not increase significantly until the
sample was heated to 38°C. When the solution was cooled from 42°C to 26°C, the OD 350 value
decreased from 1.322 (+/- 0.004) to 0.241 (+/- 0.018), showing the EGF-ELP was able to be
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solubilized after forming aggregates. Although, there was not a noticeable difference in the OD
350 value until the temperature was decreased to 36°C.
2.4.4 EGF-ELP Partially Solubilizes When Below Tt
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Figure 12 EGF-ELP particle size distribution at 4°C. EGF-ELP was diluted in PBS to a
concentration of 5 µM and analyzed at 4°C using DLS. Particle size distribution is
represented as mean intensity (%).
Further data relating to EGF-ELP thermoresponsive behavior was obtained using
dynamic light scattering (DLS). DLS was conducted below the transition temperature (4°C) and
above the transition temperature (37°C) to determine the size of EGF-ELP monomers and
aggregates, and determine the particle size distribution. 3 measurements were recorded at each
temperature. At 4°C, the Z-average value of the EGF-ELP was 61.00 nm with an average PDI
value of 0.377 (data not shown).
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Figure 12 (previous page) contains DLS data comparing the mean intensity as a function
of EGF-ELP particle size. From Figure 12, it can be concluded that the particle size distribution
is multimodal, with an approximate range of 5.61 nm-5560 nm. Relative maxima for mean
intensity are found at 11.7 nm (4.7%) and 5560 nm (3.8%) with an absolute maximum at 142 nm
(4.9%)
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Figure 13 EGF-ELP particle size distribution at 37°C. EGF-ELP was diluted in PBS to
a concentration of 5 µM and analyzed at 37°C using DLS. Particle size distribution is
represented as mean intensity (%).
When DLS was conducted at 37°C, the Z-average of the EGF-ELP aggregates was
determined to be 684.15 nm with an average PDI of 0.055 (data not shown). The relatively low
PDI value indicates the Z-average value is reliable and that the data is monodispersed. Figure 13
(above) provides data relating the % intensity and particle sizes. Figure 13 shows the particle size
distribution is monomodal and monodispersed, with a range of approximately 459 nm-1100 nm.
27

The maximum mean intensity value was found to occur at 712 nm with a mean intensity value of
25.7%.
2.4.5 EGF-ELP Induces Proliferation of A549 Cells
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EGF-ELP 19.5 µM

*
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0
Control

rEGF 1.7 nM

EGF-ELP 0.4 µM

Treatment

Figure 14 Induced A549 cell proliferation using EGF-ELP. A549 cells were treated for
48 with the described concentration of rEGF or EGF-ELP. Cell proliferation was
quantified using a BrdU assay. For statistical significance, * = p ≤ 0.05 and ** = p ≤ 0.10.
Recombinant EGF (rEGF) has been shown to induce proliferation of non-small cell lung
cancer (NSCLC) cell lines, such as A549 adenocarcinomic epithelial cells. NSCLC cell lines
overexpress the EGFR, making them ideal to test the biological activity of the EGF-ELP [39].
Cell proliferation was measured using a bromodeoxyuridine (BrdU) assay to quantify the
synthesis of new DNA after 48 hours of treatment. The results in Figure 14 (above) show the
EGF-ELP retained the biological activity of rEGF by increasing cellular proliferation nearly 20%
when compared to the control after 48 hours of treatment for all 3 concentrations used.
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2.4.6 EGF-ELP Induces Migration of A549 Cells
Treatment
ELP

EGF-ELP

20 X

Magnification

10 X

Control

Figure 15 EGF-ELP induced A549 migration. A549 cells were treated with ELP
or EGF-ELP (5 µM) for 48 hours, after which cells were stained with calcein to
aid in visualization of cell morphology and migration.
EGF has also been shown to induce the migration of A549 cells [40]. To further
investigate the biological activity of the EGF-ELP, A549 cells were treated with serum free
media as a control, ELP or EGF-ELP (5 µM) for 48 hours, after which they were stained with
calcein and photographed to observe differences in migration patterns. Figure 15 (above) shows
the results. Treatment with ELP did not produce any change in cell or cell colony morphology
when compared to the control group, with both forming tightly packed colonies. Treatment with
EGF-ELP induced a change in cell morphology compared to the control and ELP treatment.
A549 cells treated with EGF-ELP appear to have an elongated morphology and do not form
distinct colonies as the control and ELP treated cells do.

29

2.4.7 EGF-ELP Inhibits Proliferation of A431 Cells
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Figure 16 Inhibition of A431 cellular proliferation with EGF-ELP. A431 cells were
treated with various amounts of EGF-ELP and ELP for 48 hours. Cells nuclei were
stained with NucBlue and dead cell nuclei were stained with ethidium homodimer, and
then counted using an ImageJ macro.
It has been demonstrated that EGF is able to inhibit cell proliferation of certain cells
overexpressing the EGFR, such as A431 epidermoid carcinoma cells [41]. To determine whether
the EGF-ELP was biologically active, A431 cells were treated with various concentrations of
ELP or EGF-ELP for 48 hours, after which the number of live cells was counted. Figure 16
(above) shows the results of the biological activity assay after being normalized to the untreated
control. When A431 cells were treated with EGF-ELP (5 µM, 10µM, and 15 µM), the number of
live cells counted decreased by nearly 50% when compared to the untreated control and the ELP
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controls. ELP controls did not experience a statistically significant increase or decrease in cell
count after 48 hours of treatment when compared to the untreated control.
2.4.8 Induction of Human Skin Fibroblast Proliferation Using EGF-ELP
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Figure 17 Proliferation of human skin fibroblast using EGF-ELP. Fibroblasts were
treated for 48 hours in serum-free media, after which a Hoescht assay was conducted to
determine cell proliferation. * denotes a p value ≤ 0.05.
EGF has been shown to promote cellular proliferation in human fibroblast [42, 43]. So to
further test the biological activity of the EGF-ELP, human skin fibroblasts were treated with
EGF-ELP for 48 hours and a Hoescht assay was performed to determine cell proliferation. The
data (Figure 17, above) shows that the EGF-ELP does induce proliferation of human skin
fibroblasts when compared to serum-free controls and ELP controls. Both EGF-ELP treatments,
5 µM and 15 µM, caused an approximately 45% increase in cell proliferation. ELP treatments
did not cause any statistically significant increase in fibroblast proliferation.
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2.5 Discussion
The aim of this study was to create an EGF-ELP fusion protein that could be used for
regenerative medicine applications. Exogenous EGF has been used in regenerative medicine with
moderate success to treat acute wounds, but minimal success has been seen in chronic wounds.
This has been attributed to the harsh microenvironment in chronic wounds, which leads to
enhanced degradation of exogenous growth factors [30, 31]. Additionally, EGF is typically
administered in a bolus solution, which allows EGF to easily diffuse away from the injection
site. Both increased degradation and diffusion lead to poor bioavailability of the growth factor;
hence, minimal improvements are seen with EGF administration in chronic wounds [32].
The EGF-ELP fusion protein we have fabricated may assists in overcoming these hurdles
in EGF administration. To start, the ability to undergo self-assembly at physiological temperature
may allow for the formation of drug depots at the injection site, increasing the local
concentration of EGF and possibly limiting diffusion of EGF. In addition, the EGF-ELP fusion
protein can be used to create EGF-ELP infused hydrogels, similar to fibrin hydrogels infused
with KGF-ELP fusion protein [18]. The ELP domain of the EGF-ELP could also be crosslinked
with a scaffold to immobilize EGF, thereby creating a concentration gradient promoting cell
migration and proliferation into the scaffold which could further aid tissue regeneration [38].
Another benefit of the EGF-ELP fusion protein is the drug and drug carrier are one and produced
as one by bacteria, removing the need to physically or chemically conjugate EGF with a delivery
vehicle.
The biological activity assays using human skin fibroblasts, A549 cancer cells, and A431
cancer cells all show the EGF-ELP retains the biological activity of EGF. In particular, the
proliferation of fibroblast and induced migration of A549 cells demonstrates the potential for the
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EGF-ELP to be used for wound regeneration as fibroblast and epithelial cell proliferation and
migration are important components of the wound healing process, such as granulation tissue
formation and epithelialization [44-46]. Although, the treatments did not appear to show any
dose dependence. This is likely due to a dose threshold being reached using EGF-ELP. Future
studies will use lower concentrations of EGF-ELP to determine the most effective concentration.
Additionally, further experiments will be necessary to compare the regenerative capabilities of
the EGF-ELP and rEGF. The migration of A549 cells will also need to be quantified to ensure
the images are showing enhanced migration of A549 cells treated with EGF-ELP.
In addition to possessing the biological activity of EGF, the EGF-ELP retained the ability
to undergo inverse phase transition, though the phase transitioning may have been impeded by
the addition of EGF to the ELP. The OD350 data shows that the EGF-ELP fully retains the
inverse phase transition property the ELP [47]. However, DLS data and the western blot show
the fusion protein is not completely soluble. It is clear to see in the western blot that the fusion
protein was not able to completely solubilize during ITC. The DLS data supports this further as
shown by the presence of aggregates when the EGF-ELP solution was below the transition
temperature (4°C). This may be the result of cysteine bonds forming between the EGF and ELP
portions of the fusion protein rendering it less soluble, though this is unlikely due to the EGFELP retaining the biological activity of EGF [22]. This could also be caused by the relative
hydrophobicity of EGF when compared to the ELP. The discrepancy between the OD350 and
DLS data could be attributed to the increased sensitivity of DLS apparatus when compared to the
spectrophotometer.
Even though the fusion protein was not able to completely solubilize, the EGF-ELP was
purified via ITC. This could provide a relatively simple and inexpensive purification technique
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for recombinant EGF when compared to affinity chromatography methods. Furthermore, it was
found that by adding a hydrophilic FLAG-tag to the C-terminus of the fusion protein, EGF-ELP
yields increased up to 3 times (data not shown). Size data for the FLAG-tagged ELP was
obtained using DLS, (Appendix B). Further analysis will be conducted to determine the effect
the FLAG-tag has on EGF-ELP biological activity.
Hence, we were able to develop a fusion protein that retained the biological activity of
EGF and the inverse phase transition behavior of ELPs. Since the fusion protein was able to at
least partially retain inverse transition properties, purification can be carried out using a simple
ITC protocol. As demonstrated by biological activity assays, the EGF-ELP fusion protein has the
potential to be used in the treatment of chronic wounds. In regenerative medicine applications
the EGF-ELP could be used to increase the bioavailability of EGF via drug depot formation or
conjugation to a scaffold. Treatment may be further enhanced if combined with other therapeutic
ELP fusion proteins.
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CHAPTER 3: DEVELOPMENT OF ELASTIN LIKE POLYPEPTIDE BASED
HYDROGEL USING PHOTOREACTIVE AMINO ACID ANALOGS
3.1 Introduction
The regeneration of lost tissue function is one of the biggest challenges facing clinicians
and researchers, currently. The loss of tissue function can be the result of several types of
occurrences, including trauma, degenerative disease, congenital disease, or oncologic resections
[48, 49]. The treatment of these injuries is traditionally conducted using allografts [50],
xenografts [51], tissue/organ transplants [52], or synthetic biomaterials that replace the lost tissue
[53]; however, these approaches do not always produce adequate results. The prominence of
poor outcomes can be attributed to a variety of factors such as immune rejection, the need for
patients to undergo complex surgical procedures, and tissue/organ donor shortages [54, 55].
Hence, novel approaches have been investigated to aid in the restoration of lost tissue function.
One approach that has shown great potential in the restoration of lost tissue function is
the combined use of growth factors, cells, and biomaterials to replicate a microenvironment that
promotes tissue regeneration [56, 57]. Though, this approach presents its own obstacles that must
be overcome. Two of the main factors limiting the utilization of this approach are the short halflife and limited bioavailability of exogenous growth factors [58]. The importance of biomaterials
becomes apparent when considering these problems, as demonstrated by the fact that many new
growth factor delivery systems utilize biomaterials for drug delivery. The main advantage
provided by biomaterials is the ability to physically encapsulate growth factors within the
material, which protects growth factors from degradation at the injury site. Biomaterials also
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assist in maintaining sufficient growth factor concentrations at the injury site by providing a
means of localized delivery and reducing diffusion away from the wound site. This removes the
need to continuously reapply growth factors during therapy, decreasing costs and reducing the
risk of adverse effects due to supraphysiological concentrations of growth factors. Furthermore,
biomaterials can also function as structural scaffolds for host cell migration, further enhancing
tissue regeneration [33].
3.1.1 Synthetic Biomaterials Used For Regenerative Medicine
There are a number of synthetic materials used for the delivery of growth factors. Some
of the more traditional synthetics are poly-lactic acid (PLA) [59], polyglycolic acid (PGA) [60],
polyethylene glycol (PEG) [61], and copolymers such as polylactic-co-glycolic acid (PLGA)
[62]. The primary benefit of using synthetic materials is the ability to manipulate the material
properties based on the clinical application. For example, certain applications, such as bone and
cartilage engineering, require the construction of scaffolds that will retain their physical and
chemical properties over a significant period of time; hence, a nonbiodegradable polymer, such
as PEG, can be used [61, 63]. Different applications may require the scaffold to degrade at the
same rate as tissue regeneration. In these instances, biodegradable synthetic materials such as
PLA [59] or PGA [60] can be used to construct the scaffold.
While synthetic materials are highly tunable making them suitable for various
applications, there are drawbacks. One of the major limitations is the inherent lack of intrinsic
biological activity in synthetic materials, such as cell adhesion, migration, and cell mediated
degradation [64]. Thus, to surmount these issues synthetic materials have been functionalized
with various biologically active groups such as heparin to improve growth factor loading [65], or
RGD sequences to improve cell adhesion on PEG scaffolds [61]. However, the addition of
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biologically active moieties requires chemical conjugation to the scaffold, which adds another
step and time to scaffold construction. Furthermore, special considerations must be taken when
using synthetic materials because they, or their degradation products, may be toxic or difficult to
remove from the body [33].
3.1.2 Naturally Derived Biomaterials Used for Regenerative Medicine
In addition to synthetic materials, naturally derived biomaterials such as collagen [66],
gelatin [67], chitosan [68], fibrin [69], and elastin [70] have also been utilized for growth factor
delivery in regenerative medicine. The use of naturally derived materials provides many benefits
for regenerative therapy. For one, natural materials minimize inflammation associated with the
implantation of biomaterials because of their natural origin. Also, many naturally derived
biomaterials possess intrinsic biological activity that supports tissue regeneration, further
enhancing the regenerative capability of the delivery system. Lastly, since most naturally based
materials are soluble in water, their fabrication can be carried out under conditions that do not
alter the biological activity of the biomaterial or associated growth factors [33].
When used in combination with natural materials, growth factors are typically infused
into the scaffold or dispersed within the biomaterial before scaffold polymerization. The release
of growth factor is then determined by the scaffold’s degradation rate and the rate of growth
factor diffusion out of the scaffold. This can present a problem because it can be difficult to
control the rate of scaffold degradation and since growth factors are not conjugated to the
biomaterial itself, growth factors can readily diffuse out of the scaffold leading to burst release
profiles [33]. To gain control over growth factor release profiles, modifications to the biomaterial
can be made so that growth factors can bind to the biomaterial more effectively, similar to
approaches taken using synthetic materials. For instance, EGF infused hydrogels have been used
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for corneal epithelial wound healing. However, it was found that when cationized gelatin
hydrogels were used, the interaction between the cationized gelatin and EGF allowed for
increased control over EGF release. The increased control over the EGF release profile resulted
in improved corneal wound healing [26]. Additionally, heparinized chitosan has been used to
bind FGF and better control FGF release from chitosan scaffolds [71].
3.1.3 Elastin Like Polypeptides in Regenerative Medicine
As mentioned in Chapter 1, ELPs are a class of genetically encodable, nonimmunogenic,
biodegradable polymeric proteins. The amino acid sequence consists of the pentapeptide repeat
(VPGXG)n where X is any guest residue other than proline and n is the number of pentapeptide
repeats. Since ELPs are genetically encodable, it is possible to encode biologically active
molecules into an ELP sequence, creating biologically active ELP fusion proteins. ELPs also
have the ability to undergo inverse phase transitioning near physiological temperatures. When
below their inverse phase transition temperature (Tt), ELPs are soluble in aqueous solution.
Although, when above their Tt ELPs undergo self-assembly, making them insoluble in aqueous
solution. This property is conserved in ELP fusion proteins, providing means of purification for
ELPs and ELP fusion proteins via inverse transition cycling (ITC) [2].
The ability to self-assemble also enables ELPs to form nanoparticles and coacervates.
Hence, ELPs can be applied to injury sites to serve as not only drug depots, but as drug delivery
vehicles for biologically active moieties. Additionally, physiosorption or chemical conjugation of
peptide sequences to ELPs is not required since they are genetically encodable, making synthesis
of the drug and drug delivery vehicle a single step. The physical properties of ELPs can also be
fine-tuned by making alterations to ELP chain length and guest residue identity. For instance,
ELPs that form micelles have been designed using block copolymers. Moreover, ELP sequences
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have been constructed that allows for the formation of hydrogels via physical or covalent
crosslinking [2].
3.1.4 Hydrogels as Drug Delivery Vehicles in Regenerative Medicine
Hydrogels are three-dimensional networks composed of hydrophilic polymers that are
covalently crosslinked to one another, or are held together through intramolecular and
intermolecular physical interactions. Hydrogels are able to absorb large quantities of water and
biological fluids without dissolving; hence, hydrogels are able to effectively encapsulate and
release many important biomolecules, such as growth factors. Also, hydrogels are highly
permeable to oxygen and nutrients, and can be engineered to allow cell adhesion and migration
making them useful for tissue regeneration. Additionally, the high water content of hydrogels
gives them mechanical properties similar to that of soft tissues. When combined, these properties
make hydrogels remarkably attractive options for regenerative medicine applications [72].
Hydrogel formulations that can be injected in an aqueous form and then crosslinked in situ are
especially useful because it allows the hydrogel to form to the shape of the defect, providing an
improved fit at the wound site [33].
3.1.5 Hydrogels Through Physical Interactions
One of the many ways to categorize hydrogels is the method by which their polymer
network is crosslinked. Physical crosslinking is a common method utilized for hydrogel
formation and can be accomplished via ionic interaction, hydrogen bonding, and hydrophobic
interactions [72]. Hydrogels prepared through ionic interactions are formed when charged sites
on the polymer backbone interact and hold polymer chains together. This method has been used
to synthesize chitosan-alginate hydrogels for the controlled delivery of ampicillin [73].
Hydrogels formed via hydrogen bonds are crosslinked by the interaction between electron
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deficient hydrogen atoms (protons) and functional groups with high electronegativity. Hydrogen
bonding has been used to produce poly(vinyl alcohol)/DNA hydrogels for gene therapy [74].
Lastly, to form hydrogels via hydrophobic interactions, polymer chains containing hydrophobic
micro-domains are used. The hydrophobic portions of the polymer backbone act as the
crosslinking domains for the hydrogel. ELP hydrogels have been synthesized using hydrophobic
interactions between triblock polymers; though, as with many physically crosslinked hydrogels,
the hydrogel did not possess sufficient mechanical strength [2, 75].
3.1.6 Covalent Binding of Hydrogels via Chemical Crosslinking
To improve the mechanical strength of ELP based hydrogel platforms, various covalent
crosslinking methods of ELPs have been employed. McMillan and Conticello demonstrated that
periodic lysine residues could be crosslinked using bis(sulfosuccinimidyl) suberate [19].
Numerous other crosslinking agents, such as tri-succinimidyl aminotriacetate [76],
glutaraldehyde [77], transglutaminase [78], and genipin [79] have been used to covalently
crosslink

ELPs

via

lysine

and

glutamine

residues,

predominantly.

Furthermore,

[Tris(hydroxymethyl)phosphine]propionic acid[betaine] has been used to create injectable
hydrogels composed of ELP polymers [80]. Even though the use of chemical crosslinking for
hydrogel preparation has proven useful, there are disadvantages to this approach. The primary
concern is the use of crosslinking agents themselves. These crosslinking agents are often
nonspecific and require the use of toxic solvents that could negatively affect cell viability [81].
Additionally, hydrogel formation is initiated immediately after the addition of the crosslinker.
This results in the formation of non-homogenous hydrogels, which may have significant impacts
on tissue regeneration at the cellular level [82]. Figure 18 (next page) illustrates how covalent
crosslinking of ELP monomers can be used to produce hydrogels.

40

H2O

H2O

H2O
H2O

H2O
H2O

H2O

Crosslinking
H2O

H2O

H2O

H2O

H 2O

H 2O

H 2O
H2O

H2O

= ELP Mononmers

= Covalent Crosslinks

Figure 18 Covalent crosslinking for hydrogel formation. ELP monomers in aqueous
solution can be covalently crosslinked creating a polymer network that can retain water.
3.1.7 Photocrosslinkable Polymers
Photocrosslinking can be utilized to combat many of the issues associated with physical
and chemical crosslinking. Harnessing light as a crosslinking agent is an attractive option for
several reason, including the rapid rate of reaction, low energy requirements, use of solvent free
formulations, and low cost. In addition, focused light sources and photomasks can be used during
photocrosslinking to provide spatial and temporal control [82]. As a result of these findings,
polymers have been functionalized with photoreactive functional groups, such as methacrylate
[83], diazirine [82], or aryl-azides [84] to create photocrosslinkable hydrogels. However, these
platforms have one major drawback, the functionalization of the polymer backbone adds
additional steps to the synthesis of the hydrogel. One step for the functionalization of the
polymer, and another step for the removal of photoreactive groups that have not been
incorporated. To remove the need for conjugation of photoreactive functional groups,
photoreactive amino acid analogs have been utilized to create photoreactive recombinant
proteins [20].
The use of photoreactive amino acid analogs provides many benefits over the conjugation
of photoreactive moieties. To start, since recombinant proteins are genetically encodable, it is
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possible to incorporate the photoreactive amino acid analogs at specific points in the protein
sequence. Also, photoreactive amino acid analogs can be activated without the use of
photoinitiator. Finally, photoreactive amino acids do not effect phase transition properties of
ELPs, thus photoreactive polymers can be readily purified using ITC [20]. Photoreactive ELP
based films have been described using para-azidophenylalanine (pN3Phe) as a photoreactive
amino acid analog. However, the incorporation of pN3Phe into the ELP sequence required
alterations to the bacterial translational machinery due to the difference in structure between
pN3Phe and naturally occurring phenylalanine [20].
O

O

OH
N

OH

N
NH2

NH2

Photoleucine

Leucine

Figure 19 Structures of photoleucine and leucine. In photoleucine, a methyl group on
the γ-carbon is replaced by a dizarine group.
A new class of photoreactive amino acid analogs has been developed to overcome the
need for modification of bacterial translational machinery. This new class has photoreactive
diazirine rings incorporated into the amino acid side chain, as shown in Figure 19 (above). Due
to the similarity in structure between the naturally occurring amino acids and the photoreactive
analogs, there is no need to modify the bacterial translational machinery for the analog to be
incorporated into the protein sequence. Furthermore, the diazirine chemistry can readily
activated using long wave ultraviolet (UV) light (330-370 nm) and the crosslinking reaction is
noncytotoxic, meaning crosslinking can be conducted in situ [85]. To further improve
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incorporation of photoreactive amino acids, auxotrophic bacteria can be used for protein
expression.
3.1.8 Noncanonical Amino Acid Substitution
Protein polymers have been used to create a variety of functional biomaterials. However,
the side chains of canonical amino acid residues they are composed of limit their functionality.
To further expand the functionality of protein polymers, noncanonical amino acid analogues,
such as photoreactive amino acids, have been incorporated into recombinant proteins [20]. To
incorporate noncanonical amino acids, auxotrophic bacterial expression host are typically used
[86]. In auxotrophic bacteria, genes for biosynthetic pathways that produce specific canonical
amino acids have been knocked out, thereby reducing the bacteria’s ability to produce certain
amino acids. This is advantageous because if the auxotrophic bacteria are starved of the
canonical amino acid for which they are auxotrophic, and a noncanonical analog of the amino
acid is added to the expression media, there will be an increased rate of noncanonical amino acid
incorporation; thereby allowing for increased functionalization of protein polymers.
The substitution of noncanonical amino acid analogs was originally limited to analogs
with structural similarity to the canonical amino acids. Similarities in structure allow
noncanonical amino acids to avoid the proofreading mechanisms in the translational machinery.
However, the number of noncanonical amino acids available has been expanded to include
analogs with dissimilar structures through the manipulation of protein expression host’s
biosynthetic machinery [86]. For instance, mutated amino-acyl tRNA synthetases have been
introduced into E. coli that possess enlarged binding domains [87] or reduced editing activity
[88] to improve the incorporation of noncanonical amino acids.
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3.2 Project Objective
There have been a number of platforms developed that serve as drug carriers and
structural scaffolds. However, these systems typically require either physiosorbtion or chemical
conjugation of biologically active moieties and crosslinking domains to the scaffold, making
their synthesis more complicated and time consuming. Additionally, many of these platforms use
cytotoxic crosslinking agents, and cannot be injected into a defect in aqueous form and
crosslinked in situ, providing a better fit at the defect site. The aim of this project was to develop
a platform that not only serves as a drug delivery vehicle and structural scaffold, but also
removes the need for conjugation of bioactive peptides and crosslinking motifs to the material,
and is able to be crosslinked in situ after injection in an aqueous form. To achieve these goals,
we set out to create a novel class of photocrosslinkable and biologically active ELPs that can be
synthesized in a single step.
3.3 Materials and Methods
3.3.1 Materials
The monomeric gene fragment encoding (VPGLG)5(VPGVG) (referred to as L5) was
purchased from GenScript. Restriction enzymes and other enzymes used for cloning were
purchased from New England Biolabs. For purification of DNA after gel electrophoresis, a gel
extraction kit (Qiagen) was used. Naturally occurring amino acids and L-photoleucine were
supplied by ThermoFisher Scientific. JW5807-2 leucine auxotrophic Escherichia coli developed
by Baba et al were used for protein expression [89].
3.3.2 ELP Gene Construction
The ELP gene was constructed using a monomeric gene fragment encoding the L5 ELP
sequence. The monomeric gene fragment was excised from the pUC19 cloning plasmid using
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PflMI and BglI restriction endonucleases, and the pUC19 cloning vector was linearized using
BglI. Following gel electrophoresis and purification, the excised gene fragment underwent
concatemerization to produce a gene encoding 3 monomeric gene fragment repeats. The newly
synthesized gene was then ligated into the linearized L5- pUC19 vector. This ligation produced a
gene encoding L20. The L20 pUC19 plasmid was then transformed into Top10f competent cells
(Invitrogen). PCR was used to select bacterial colonies containing the L20 plasmid.
Excision of L5,
linearization of
pUC19, and
concatemerization
L5-pUC19
L15 gene

= L5
gene

+

+

L5-pUC19

Ligation

L20-pUC19

Excision of L20,
linearization of
L20-pUC19

L20-pUC19

L20
gene

Ligation

L40-pUC19

Figure 20 Construction of L40 (ELP) pUC19 cloning vector. The L40 gene was
constructed from a L5 monomeric gene fragment. The L40 gene was then excised and
ligated into a linearized FLAG-pUC19 vector to create a L40-FLAG gene, which was
ligated into a pET25b(+) expression vector (not shown).
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The L20 gene was then removed from the pUC19 plasmid using PflMI and BglI, and the
L20 pUC19 plasmid was also linearized using BglI. After purification, the L20 gene was then
ligated into the linearized L20-pUC19 plasmid to produce a L40-pUC 19 plasmid. The L40-pUC19
plasmid was transformed into Top10f competent cells, and PCR was used to select for bacterial
colonies containing the correct plasmid. Figure 20 (previous page) illustrates the cloning process
up to this point. The L40 gene was then removed from the pUC19 cloning plasmid using PflMI
and BglI, and purified. The L40 gene was then ligated into a linearized FLAG-pUC19 plasmid
(FLAG-tag was placed at C-terminus of ELP) and transformed into Top10f competent cells. PCR
was used to select bacterial colonies containing the appropriate plasmid.
The L40-FLAG gene (ELP) was then removed from the pUC19 plasmid, purified, and
ligated into a pET25b(+) expression plasmid linearized with SfiI restriction endonuclease. Again,
Top10f competent cells were used to transform the plasmid. Bacterial colonies underwent PCR
and plasmids containing the L40-FLAG gene were sent for DNA sequencing to ensure the correct
gene was produced and that there were no genetic mutations. Once the DNA sequence was
confirmed, L40-FLAG pET25b(+) expression plasmids were transformed into JW5807-2 leucine
auxotrophic E. coli for ELP expression.
3.3.3 Photoreactive ELP Expression
Leucine auxotrophic E. coli transformed with the pET25b(+) expression system
containing the ELP gene were used to produce ELPs. Due to the inability of the bacteria to grow
in standard M9 minimal media (Na2HPO4: 6 g/L , KH2PO4: 3 g/L, NaCl: 0.5 g/L, NH4Cl: 1 g/L,
MgSO4: 1 mM, CaCl2: 100 µM, glycerol: 0.2%, and carbenicillin: 100 µg/ml), a starter culture
of TB media (no glycerol) containing 1% glucose as a carbon source was used as a starter culture
for bacteria. The presence of 1% glucose as a carbon source prevented activation of the
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pET25b(+) expression system containing the ELP gene. Inhibition of ELP expression is
necessary until photoleucine has been added to media to maximize photoleucine incorporation.
Following overnight inoculation of bacteria in TB media, the overnight culture was added
directly to standard M9 minimal media containing 1% glucose (1 ml TB culture : 20 ml fresh
M9) until the culture reached an OD600 value of 0.7. Once the desired OD600 value was
reached, the bacteria was centrifuged and washed in PBS to remove excess TB media. Bacteria
were centrifuged again and resuspended in M9 minimal media containing the appropriate amount
of supplemental amino acids, photoleucine, and isopropyl β-D-1-thiogalactopyranoside (IPTG)
(1 mM) for ELP expression. Induction of ELP expression with IPTG lasted for 6-24 hours. The
ELP expression protocol is described in Figure 21 (below).
TB media
- 1% glucose
- Cultured
overnight

M9 + TB
media
- 1:20 dilution
- 1% glucose
- OD600 = 0.7

M9 media
- Photoleucine
- Amino Acids
- IPTG

Figure 21 Photoreactive ELP expression. Leucine auxotrophic expression host were
originally cultured in TB media containing 1% glucose, then transferred to fresh M9
media containing 1% glucose (1 ml TB: 19 mL M9) until sufficient levels of bacterial
growth had been attained. Bacteria were then washed and resuspended in fresh M9
media supplemented with amino acids and IPTG to induce ELP expression.
3.3.4 In vivo Photocrosslinking
Photocrosslinking was conducted using a Blak-Ray® B-100AP/R High Intensity UV
Lamp (365 nm, 100 watt, 60 Hz). Following induction of ELP expression, expression host were
centrifuged and resuspended in 3 mL of 1x PBS. Bacteria suspension was placed in a 6 well
tissue culture plate and exposed to UV light for 5 minutes. Following UV exposure, bacteria was
centrifuged and lysed. The mechanism for photocrosslinking is illustrated in Figure 22 (next
page).
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Figure 22 Photocrosslinking mechanism using photoleucine. UV radiation (~350 nm)
causes carbene formation on photoleucine side chains. Carbene can react with any
nearby amino acid side chains forming covalent crosslinks with ELP monomers.
3.3.5 Western Blot Analysis
Bacterial lysates were prepared and underwent SDS-PAGE analysis (12 % acrylamide).
ELPs were labeled with anti-FLAG antibody (Sigma Aldrich), which was labeled using
horseradish peroxidase (HRP) linked anti-rabbit secondary antibody (Cell Signal). A
chemiluminescent signal to identify HRP-linked anti-rabbit was produced using LumiGLO
Reagent and peroxide (Cell Signal).
3.4 Results
3.4.1 Inhibition of pET25b(+) Expression System Using 1% Glucose
To determine whether glucose was able to effectively suppress the pET25b(+) expression
system used for ELP production, E. coli containing the FLAG-tagged ELP gene within the pET
expression system was cultured for 24 hours in TB media with either 1% glucose or 1% glycerol
used as a carbon source. Figure 23 (next page) depicts the results of SDS-PAGE analysis and
Table 3 (next page) describes carbon source used for expression media. The presence of a protein
band near 25 kDa in Lane 2 indicates the ELP gene was expressed when 1 % glycerol was
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utilized as a carbon source (molecular weight of-ELP=20.2 kDa). However, the absence of the
same band in Lane 1 suggests the pET system was inhibited since the ELP was not expressed in
the presence of 1% glucose.
Table 3 Lane descriptions for Figure 23
Lane

Description

L

Biotin ladder

1

1% glucose

2

1% glycerol

30 kDa

20 kDa
L

1

2

Figure 23 Glucose suppression of ELP expression. E. coli were cultured in TB media in
the presence of 1% glucose or 1% glycerol. The presence of FLAG-tagged ELPs was
detected via western blot analysis using anti-FLAG.
3.4.2 ELP Photocrosslinking in vivo
Figure 24 (next page) displays a western blot completed on bacterial lysates after
exposure to UV radiation, while Table 4 (next page) describes the expression media conditions,
and whether or not expression host were exposed to UV light. Leucine auxotrophic E. coli were
cultured in M9 minimal media containing valine (1 mg/ml), proline (1 mg/ml), glycine (2
mg/ml), and either leucine (1 mg/ml) or photoleucine (1 mg/ml). Lanes 1-4 contain protein bands
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at approximately 25 kDa, denoting the presence of ELP monomers that have not been
photocrossinked. Though, Lane 1 contains an additional band at nearly 50 kDa indicating the
presence of photocrosslinked ELP, possibly an ELP dimer. The increased signal in Lane 4
indicates elevated ELP expression levels when compared to Lane 2 and Lane 3. Due to the
apparent crosslinking of ELP monomers in Lane 1, it is difficult to determine the relative amount
of protein expression compared to other samples.
Table 4 Lane descriptions for Figure 24
Lane

Description

L

Biotin Ladder

1

p-Leu and UV

2

p-Leu and no UV

3

Leucine and UV

4

Valine, Proline, Glycine, and UV

50 kDa

Crosslinked ELP

40 kDa
30 kDa

20 kDa
L

1

2

3

4

Figure 24 In vivo photocrosslinking of ELP. Leucine auxotrophic E. coli was cultured in
M9 minimal media (All media contained valine, proline, and glycine) supplemented with
photo-leucine or leucine. After exposure to UV light, western blot analysis was
conducted using anti-FLAG to detect the presence of crosslinked ELP’s.
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3.4.3 Valine Induced ELP Expression
Table 5 Lane descriptions for Figure 25
Lane

Description

L

Biotin Ladder

1

1 mg Photoleucine

2

1 mg Leucine

3

No Amino Acids

4

1 mg Valine

5

1 mg Proline and Glycine

30 kDa

20 kDa
L

1

2

3

4

5

Figure 25 Increased ELP expression when growth media is supplemented with
valine. M9 minimal media was supplemented with the described amino acids (Table
5) and inoculated for 24 hours for ELP expression.
To investigate the possibility that valine was enhancing ELP expression, a western blot
was conducted on bacterial lysates from bacteria cultured in various expression medias for 6
hours. Figure 25 (above) shows the results of the western blot and Table 5 (above) defines the
contents of the expression media used to culture bacteria. Bacteria cultured with leucine, valine,
proline and glycine, and no additional amino acids expressed the ELP as evidenced by the
protein band at 25 kDa; though, expression occured in different amounts. Bacteria cultured in the
presence of proline and glycine, or no amino acids produced less ELP than those cultured in the
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presence of leucine and valine. Futhermore, bacteria inoculated in the presence of valine had the
highest amount of ELP expression, even more than bacteria cultured with leucine. The bacteria
cultured with photoleucine produced the smallest quantity of ELP, just enough to register a
signal.
3.4.4 Photoleucine Inhibits ELP Expression
Table 6 Lane descriptions for Figure 26
Lane

Description

L

Biotin Ladder

1

1 % glucose

2

0.5 mg Leucine

3

0.1 mg Photoleucine

4

0.5 mg Photoleucine

5

1 mg Photoleucine

30 kDa

20 kDa
L

1

2

3

4

5

Figure 26 Addition of photoleucine to expression media reduces ELP
expression. Leucine auxotrophic E. coli were cultured in M9 minimal media
supplemented with the described amino acids (Table 6) for 24 hours.
To examine the effect of photoleucine on ELP expression, ELPs were expressed in M9
minimal media for 6 hours containing either leucine or various amounts of photoleucine. The
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results of western blot analysis are presented in Figure 26 (previous page) and Table 6 (previous
page) describes the expression media used to culture the bacteria that was used in each lane.
Lane 1, containing the bacterial lysate from the overnight culture with 1% glucose, was used as a
control to guarantee no ELP was being expressed while in TB media. As shown in the Figure 26,
there was no ELP expression in the overnight starter culture. The only culture that appears to
have expressed the ELP was the bacteria culture supplemented with leucine as indicated by the
signal seen near 25 kDa, which is close to the approximate weight of the ELP monomers. When
media containing 0.1 mg, 0.5 mg, and 1.0 mg of photoleucine was used for ELP expression, no
ELP was expressed.
3.4.5 Optimization of the Leucine:Photoleucine Ratio in Expression Media
To determine the ratio of leucine:photoleucine that would be optimal for ELP expression,
bacteria was cultured in M9 minimal media containing various ratios of leucine:photoleucine.
ELP expression was induced for 6 hours. Results of the western blot analysis are exhibited in
Figure 27 (next page), while the ratio of leucine:photoleucine used in expression media is
described in Table 7 (next page). The overnight control bacteria cultured in 1% glucose did not
produce any ELP, as expected. The bacteria cultured in media containing only photoleucine
(Lane 2), did not express any ELP after inoculation; however, the remainder of the bacterial
lysates did contain ELP. As demonstrated in Figure 25, the leucine:photoleucine ratios
responsible for the highest amounts of ELP expression were the 1:30 ratio and 1:6 ratio. When
ratios of 1:3 and 1:2 were used, ELP expression appears to have decreased slightly; though, it is
not too significant. However, when a 1:1 ratio of leucine:photoleucine was used, there was a
noticeable decrease in ELP expression when compared to other expression media that contained
leucine and photoleucine.
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Table 7 Leucine:photoleucine ratios for Figure 27
Lane

Description

L

Biotin Ladder

1

1 % glucose

2

0 mg Leucine

3

1:30 Ratio

4

1:6 Ratio

5

1:3 Ratio

6

1:2 Ratio

7

1:1 Ratio

30 kDa

20 kDa
L

1

2

3

4

5

6

7

Figure 27 Increasing the leucine:photoleucine ratio decreases ELP expression.
Leucine auxotrophic E. coli were cultured in M9 minimal media supplemented
with the described amino acids (Table 7) for 24 hours.
3.5 Discussion
The original aim of this project was to create a photocrosslinkable ELP based hydrogel
that could be synthesized in a single step (no need for conjugation, addition of crosslinking
agents, or alteration of translational machinery) using photoreactive amino acid analogs. To start,
we realized we needed to develop a protocol to culture leucine auxotrophic E. coli to levels
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sufficient for ELP expression because standard M9 media containing supplemental amino acids
was not conducive to bacteria growth. We achieved this using a combination of TB media, M9
media, and glucose. TB media was chosen for the starter culture because it provides a favorable
environment for bacteria growth. Though, TB media contains high quantities of leucine, meaning
bacteria should not express the ELP while in TB media since leucine will compete with
photoleucine for incorporation into the ELP. To inhibit ELP expression, 1% glucose was added
to the media because it has been shown the pET25b(+) expression system we used to express the
ELP can be inhibited by the presence of 1% glucose [90]. Figure 21 demonstrates the addition of
1% glucose was able to inhibit ELP expression in TB media.
The TB media culture was then diluted in M9 media containing 1% glucose (1 : 20
dilution). The reason bacteria cultured in TB media was not centrifuged and immediately
resuspended in the M9 expression media containing supplemental amino acids was we were
aiming to reduce the possibility of leucine incorporation. Since TB media contains relatively
large amounts of leucine, leucine may have been present in the cells directly following removal
from TB media. Hence, dilution of the TB culture in M9 media containing 1% glucose for 24
hours allowed bacteria to use any excess leucine for the expression of other proteins while also
supporting growth of bacteria to growth levels sufficient for ELP expression.
The bacteria present in the TB/M9 solution was then centrifuged, washed in PBS,
centrifuged again, and resuspended in M9 expression media containing 0.2 % glycerol,
supplemetal amino acids, and IPTG to induce ELP expression. This is the point at which
photoleucine could be added to the expression media. Furthermore, valine, proline, and glycine
were initially chosen as the constant supplemental amino acids because the ELP sequence
contains large quantities of those three amino acids. It must be acknowledged the bacteria in the
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expression media likely contained a small amount of excess leucine from the TB/M9 solution,
but the amonut of leucine present was significantly reduced by the original dilution and
resuspension in fresh M9 expression media.
Following induction with IPTG for 6 hours, bacteria was resuspended in PBS and
exposed to UV light to promote photocrosslinking of ELP monomers. From Figure 24, it appears
that photoactivation caused the formation of ELP dimers, showing the potentital for
photocrosslinking ELP monomers and that the expression protocol devised allowed for the
incorporation of photoleucine. However, there were two unanticipated finding. For one, the ELP
was at a slightly higher molecular weight than anticipated; though, this could be attributed to
aggregation of ELPs during SDS-PAGE analysis. Second, the western blot showed the largest
quantity of ELP was produced when only valine, proline, and glycine were substituted into the
expression media. This finding was unexpected because leucine auxotrophic E. coli were used
as expression host. In theory, since the bacteria were not able to produce their own leucine,
media not containing supplemental leucine should have had depressed levels of ELP expression
since the ELP contains a relatively significant amount of leucine residues (40 leucine residues
per ELP). However, it was found that bacteria cultured in media supplemented with valine,
proline, glycine, and leucine produced a smaller quantity of ELP when compared to media not
containing leucine. Even though it was not the original aim of the project, this phenomena was
investigated further and it was hypothesized the addition of leucine to expression media may
alter ELP expression; though, the mechanism by which this was happening was not understood.
To determine the effects of the supplemented amino acids on ELP expression, bacteria
was cultured as discussed previously, but expression was carried out in media supplemented with
either photoleucine, leucine, valine, or proline and glycine. Figure 25 demonstrates the

56

supplemented amino acids can cause ELP expression to vary. When ELP was expressed in media
with proline and glycine or no amino acids, there was no significant difference in expression
levels, suggesting the presence of proline and glycine does not alter ELP expression. Though, the
presence of leucine or valine promotes ELP expression. Moreover, the data suggests the addition
of valine to expression media enhances ELP expression when compared to leucine, supporting
the data from Figure 24. Again, the reason for this is not understood because theoretically,
leucine auxotrophic E. coli cultured in media without leucine should have minimal ELP
expression levels due to the presence of leucine residues in the ELP sequence.
Also, the results from Figure 25 showed when photoleucine was the only amino acid
added to expression media, ELP expression was reduced when compared to ELP expression in
media containing supplemental amino acids or no additional amino acids. This was unexpected
because, in theory, the bacteria being cultured in media without any supplemented amino acids
should produce the smallest quantity of ELP relative to the expression media with supplemental
amino acids. In addition, photoleucine had been reported to have no effects on protein expression
and has been incorporated into eukaryotic proteins [85]. Hence, it was originally hypothesized
the addition of photoleucine would produce the same expression levels as media supplemented
with leucine and would be incorporated into ELPs. However, these results indicated photoleucine
was reducing ELP expression.
To confirm whether or not photoleucine was impeding ELP expression, media containing
various of amounts of photoleucine and a leucine control media were used for ELP expression.
The results supported the claim that the presence of photoleucine was reducing ELP expression,
regardless of the amount added to the media. Therefore, it was determined that in order for
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photoreactive ELP expression to proceed, leucine or valine must be present in expression media
alongside photoleucine.
It was decided leucine should be added with photoleucine even though this would
theoretically increase competition for photoleucine incorporation, and ELP expression was
higher in the presence of valine. The reason leucine was chosen over valine to be used in
conjunction with photoleucine was we hypothesized valine might be incorporated preferentially
over leucine due to the increased ELP expression seen in Figure 24 and Figure 25, even though
the mechanism was not understood. If valine was incorporated preferentially over leucine, the
use of valine with photoleucine may decrease the rate of photoleucine incorporation into the
ELP. Hence, while leucine may decrease ELP expression in relation to valine, the rate of
photoleucine incorporation may be increased. We intended to find a ratio of leucine:photoleucine
that allowed for optimal ELP expression. The data in Figure 27 revealed if leucine and
photoleucine are to be used as supplemental amino acids in the ELP expression media, ELP
expression increases as the amount of leucine used is kept to a minimum. However, leucine is
required for expression of the ELP.
When this investigation was started, it was hypothesized that by simply supplementing
expression media with photoleucine and amino acids found in ELPs (valine, proline, and
glycine), photoleucine would be incoporated into the ELP. While the in vivo crosslinking
demonstrated it is possible, the same experiment caused us to question whether the expression
protocol being used was efficient. As has been previously discussed, we found the addition of
valine aids ELP expression in the leucine auxotrophic E. coli just as well, if not better, than
leucine. We also noticed that ELP expression was significantly inhibited when photoleucine was
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the sole supplemental amino acid. There are a number of explanations to explain these
occurences.
Concerning ELP expression in the presence of photoleucine, even though photoleucine is
not supposed to require the modification of translational machinery for incorporation due to the
structural similarities to leucine, there may be a need to alter the leucine-tRNA synthetase
(LeuRS) in the expression host. Tang and Tirrell demonstrated by replacing the threonine-252
residue in LeuRS with bulkier residues such as leucine, phenylalanine, or tyrosine, the
proofreading capabilites of LeuRS were reduced, allowing for incorporation of noncanonical
leucine analogs that could not be incorporated with unmodified LeuRS [88]. Another method
could be to create a mutant LeuRS with an enlarged binding pocket. By enlarging the binding
pocket of LeuRS, the specificity of LeuRS can be decreased; hence, increasing the incorporation
of photoleucine. A similar strategy has been employed to incorporate phenylalanine analogs into
recombinant proteins [20].
However, the specificity of the bacterial LeuRS may not be the reason for decreased ELP
expression in the presence of photoleucine. From Figure 25, there was less ELP expressed in
media containing photoleucine than in media containing no additional amino acids. This
indicates not only is photoleucine not being incorporated into the ELP, but it is actually
inhibiting ELP expression. Photoleucine could be having cytotoxic effects on the bacterial
expression host, though this is unlikely as photoleucine has been shown to be noncytotoxic [85].
Another possible explanation for the apparent inhibition of ELP expression is photoleucine is
being incorporated into proteins which are responsible for transcription of the ELP gene, and
impairing their function. The finding that ELP expression occurs when even a minute amount of
leucine is added to expression media with photoleucine hints this may be the problem as the
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supplemental leucine could be incorporated into the necessary proteins, allowing them to
function properly.
It was hypothesized leucine auxotrophic E. coli should not be able to produce ELP if only
valine, proline, and glycine are added to expression media because of the lack of leucine. Our
investigation reveals the addition of leucine to expression media does not enhance ELP
expression, and may actually decrease ELP expression. The reasons for this are not quite clear.
There is a possibility the bacterial LeuRS has undergone a mutation allowing valine to bypass
the editing mechanisms of LeuRS. However, this would not explain the apparent increase in ELP
expression when leucine is not added to the media. Another explanation is the possibility of
errors being made while loading the SDS-PAGE gel. If a higher concentration of bacterial lysate
was added for the bacteria cultured in leucine there may be a higher amount of ELP in the
sample, causing an increase in signal strength.
Thus, we have created a photoreactive ELP that does not require the conjugation of
functionalized moeities, addition of crosslinking agents, or manipulation of translational
machinery to undergo photocrosslinking. While we were not able to synthesize a hydrogel, the
potentital for hydrogel formation was demonstrated by the photocrosslinking of ELP monomers.
Yet, we did find expression of the photoreactive ELP was not as straightforward as initially
anticipated. Expression of the ELP and incorporation of photoleucine could not be conducted
when photoleucine was the sole amino acid added to expression media. The mechanisms behind
this are not completely understood; however, the specificity of the bacterial LeuRS could play a
significant role. Additionally, we found ELP expression was able to take place at the same rate
when valine or leucine was supplemented in expression media, possibly due to mutations in the
LeuRS of the expression hosts. Understanding how the ELP expression protocol alters ELP
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expression and photoleucine incorporation will be crucial to the future of this study as we aim to
maximize the efficiency of photoreactive ELP production.
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CHAPTER 4: THESIS CONCLUSION AND FUTURE WORK
In both studies, ELPs were used to create innovative drug delivery platforms to address
various issues in regenerative medicine. In the first study, we produced an EGF-ELP fusion
protein to aid in the delivery of exogenous EGF to chronic wounds. EGF is currently
administered using simple bolus application techniques [32, 34]. These methods do not provide a
means of protecting EGF from degradation in the chronic wound microenvironment or prevent
diffusion of EGF away from the application site; hence, there is decreased bioavailability of EGF
leading to insignificant improvements in tissue regeneration [32]. By fusing EGF with an ELP,
we were able to combine the biological activity of EGF with the inverse phase transition abilities
of ELPs. Since the fusion proteins aggregate at physiological temperatures, the EGF-ELP fusion
protein can improve the bioavailability of EGF through the formation of localized drug depots at
the application site. The EGF-ELP drug depots will not only increase the local concetration of
EGF, but also minimize diffusion of EGF away from the injection site, thereby improving tissue
regeneration. Future studies will need to be conducted in animal models to determine whether or
not the EGF-ELP does improve chronic wound healing over free exogenouos EGF in vivo.
Ultimately, we intend to conjugate the EGF-ELP to a hydrogel scaffold for drug delivery,
allowing for the formation of an EGF concentration gradient to promote cell migration into the
hydrogel.
The second portion of the thesis was meant to tackle many of the problems linked with
hydrogel synthesis. As aforementioned, there have been a range of functionalized hydrogel
platforms created that serve as drug carriers and structural scaffolds; though, many of these
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platforms require the chemical conjugation of bioactive molecules and crosslinking domains to
the hydrogel. This adds steps and time to hydrogel preparation, further complicating hydrogel
production. Furthermore, many platforms cannot be injected and undergo gelation in situ because
they utilize cytotoxic crosslinking reagents. We aimed to develop a photoreactive ELP based
hydrogel platform that could deal with these issues. Photoresponsive ELPs were expressed using
leucine auxotrophic E. coli that substitute photoleucine, a photoreactive leucine analog, for
leucine throughout the ELP sequence. When exposed to UV light, photoleucine can covalently
crosslink with nearby amino acid side chains and form a polymer network. The devised hydrogel
platform allows for the synthesis of injectable hydrogels without the need for conjugation of
crosslinking or bioactive moetieties.
In vivo crosslinking of photoreactive ELPs within the expression hosts showed the
potential for the system. However, it was also found the addition of photoleucine alone to
expression media inhibited ELP expression, and the addition of valine and leucine promoted ELP
expression at the same rate. Hence, future studies will be needed to optimize expression media
conditions for photoreactive ELP expression. Furthermore, there may be a need to modify the
translational machinery of the leucine auxotrophic E. coli, in particular the LeuRS, if
photoleucine cannot be incorporated into ELPs at a sufficient rate. Reducing the proofreading
capability or increasing the size of the binding pocket of the LeuRS may lead to increased
photoleucine incorporation [20, 88]. Also, the ELP will need to be purified, resuspended in
aqueous solution, and photocrosslinked to confirm a hydrogel can be formed.
Once the photoreactive hydrogel has been fine-tuned for hydrogel formation, it could be
used as a scaffold for the delivery of the EGF-ELP. Since the photoreactive ELP forms covalent
crosslinks with any nearby amino acid side chain, the EGF-ELP can be immobilized to the
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scaffold, potentially promoting cell migration into the scaffold and aiding in tissue regeneration.
Investigations will need to be conducted to determine the biocompatibility of the hydrogel and
the impact it has on the biological activity of the EGF-ELP. The combination of the EGF-ELP
and photoreactive ELP hydrogel could prove to be a useful tool to aid in tissue regeneration.
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APPENDIX A: AMINO ACID SEQUENCE FOR EGF AND ELP
Table A Sequence and molecular weight information for EGF and ELP
Molecular
Protein
Sequence
Weight
EGF

NSDSECPLSHDGYCLHDGVCMYIEALDKYAC
NCVVGYIGERCQYRDLKWWELR

6216 Da

ELP

(VPGVG)40[(VPGVG)2(VPGCG)(VPGVG)2] 2

20496 Da

EGF-ELP

NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRD
LKWWELR
(VPGVG)40[(VPGVG)2(VPGCG)(VPGVG)2] 2

26712 Da
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APPENDIX B: FLAG-TAGGED EGF-ELP SIZE DATA
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Figure A FLAG-tagged EGF-ELP particle size distribution at 4°C. The FLAG-tagged
EGF-ELP was diluted in PBS to a concentration of 5 µM and analyzed at 4°C using
DLS. Particle size distribution is represented as mean intensity (%). The Z-average was
found to be 76.73 nm (data not shown).
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Figure B FLAG-tagged EGF-ELP particle size distribution at 37°C. The FLAG-tagged
EGF-ELP was diluted in PBS to a concentration of 5 µM and analyzed at 37°C using
DLS. Particle size distribution is represented as mean intensity (%). The Z-average of
FLAG-tagged EGF-ELP aggregate was found to be 216.33 nm (data not shown).
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